Palisade Bio
PALI
3 hedge funds and large institutions have $1.92M invested in Palisade Bio in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
40% less funds holding
Funds holding: 5 → 3 (-2)
51% less capital invested
Capital invested by funds: $3.95M → $1.92M (-$2.03M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$684K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$655K |
| 3 |
JPCCM
J&P (China) Capital Management
Hong Kong,
China
|
-$64K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$29K |
| 5 |
GT
Greenleaf Trust
Kalamazoo,
Michigan
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$6K | – | – |
|
PALI Hedge Fund Activity: Q4 2016 in Review
3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2016, worth a combined $1.92M — down 51% from $3.95M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PALI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Alethea Capital Management, exiting entirely with an estimated $684K sold.
- 3 institutional investors held Palisade Bio (PALI) as of Q4 2016, down from 5 in Q3 2016.
- Funds reported $1.92M of Palisade Bio stock for Q4 2016, down 51% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q4 2016 and 2 closed out, a net change of -2 holders.
- The largest Palisade Bio seller in Q4 2016 was Alethea Capital Management, an estimated $684K sold.
Based on aggregated 13F filings for Q4 2016.